According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
Several other analysts have also recently weighed in on the company. BidaskClub cut Natera from a sell rating to a strong sell rating in a report on Friday, March 1st. ValuEngine raised Natera from a buy rating to a strong-buy rating in a report on Tuesday, January 15th. Finally, Canaccord Genuity reissued a buy rating and set a $25.00 price objective on shares of Natera in a report on Monday, March 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $28.00.
Natera stock opened at $18.13 on Friday. The company has a debt-to-equity ratio of 2.28, a current ratio of 2.11 and a quick ratio of 1.99. Natera has a 12-month low of $10.77 and a 12-month high of $29.62. The stock has a market capitalization of $1.17 billion, a P/E ratio of -8.43 and a beta of 1.89.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.51). Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. The business had revenue of $67.00 million during the quarter, compared to analysts’ expectations of $62.87 million. As a group, sell-side analysts predict that Natera will post -2.24 EPS for the current fiscal year.
In other Natera news, insider Jonathan Sheena sold 2,620 shares of the business’s stock in a transaction dated Friday, March 29th. The stock was sold at an average price of $20.50, for a total transaction of $53,710.00. Following the completion of the sale, the insider now directly owns 240,390 shares of the company’s stock, valued at approximately $4,927,995. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 3,192 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $16.00, for a total value of $51,072.00. Following the sale, the chief financial officer now directly owns 13,422 shares of the company’s stock, valued at $214,752. The disclosure for this sale can be found here. Insiders have sold a total of 351,313 shares of company stock valued at $7,132,873 over the last three months. Company insiders own 13.18% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. State Board of Administration of Florida Retirement System grew its position in shares of Natera by 6.7% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock worth $160,000 after buying an additional 717 shares during the period. Legal & General Group Plc grew its position in shares of Natera by 14.5% during the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after buying an additional 736 shares during the period. Alliancebernstein L.P. grew its position in shares of Natera by 7.3% during the 3rd quarter. Alliancebernstein L.P. now owns 41,000 shares of the medical research company’s stock worth $982,000 after buying an additional 2,800 shares during the period. Brandywine Managers LLC grew its position in shares of Natera by 12.9% during the 4th quarter. Brandywine Managers LLC now owns 26,200 shares of the medical research company’s stock worth $366,000 after buying an additional 3,000 shares during the period. Finally, Wells Fargo & Company MN grew its position in shares of Natera by 6.9% during the 3rd quarter. Wells Fargo & Company MN now owns 52,899 shares of the medical research company’s stock worth $1,266,000 after buying an additional 3,411 shares during the period. Institutional investors own 87.76% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.